Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: Evolution of NCCN, ASCO, and St Gallen recommendations

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 10, 2006, Pages 971-979

  Carlson, Robert W ^a   Hudis, Clifford A ^b   Pritchard, Kathy I ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Adjuvant therapy; Aromatase inhibitor; ASCO technology sssessment; Breast cancer; NCCN clinical practice guidelines; St Gallen consensus; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; HORMONE RECEPTOR; LETROZOLE; TAMOXIFEN;

ADJUVANT THERAPY; ARTHRALGIA; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; ENDOMETRIUM CANCER; FRACTURE; GYNECOLOGIC DISEASE; HORMONAL THERAPY; HUMAN; MUSCLE CRAMP; OSTEOPOROSIS; OVERALL SURVIVAL; POSTMENOPAUSE; PRACTICE GUIDELINE; THROMBOEMBOLISM; VAGINA BLEEDING; VISUAL DISORDER;

EID: 33751566813     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0082     Document Type: Article

References (32)

1. Kumar S, Leonard RC. Adjuvant hormonal therapy in early breast cancer. Oncology (Williston Park) 2005;19:1425-1428, 1433.
2. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-1618.
3. Field MJ, Lohr KN, eds. Clinical Practice Guidelines: Directions for a New Program. Washington DC: National Academy Press, 1990.
4. Browman GP, Levine MN, Mohide EA, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995;13:502-512.
5. Winn RJ, McClure JS. The NCCN clinical practice guidelines in oncology: a primer for users. J Natl Compr Canc Netw 2003;1:5-13.
6. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
7. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: up-dated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-690.
8. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-1542.
9. Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001;93:456-462.
10. Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst 1996;88:1828-1833.
11. Abrams JS. Tamoxifen: five versus ten years - is the end in sight? J Natl Cancer Inst 2001;93:662-664.
12. Baum M. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal (PM) women [abstract]. Breast Cancer Res Treat 2001;69:8. Abstract.
13. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-2139.
14. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-1810.
15. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60-62.
16. Thürlimann BJ, Keshaviah A, Mouridsen H, et al. BIG 1-98: randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer [abstract]. J Clin Oncol 2005;23(suppl):6S. Abstract 511.
17. Thurlimann BJ. BIG 1-98: randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Oral presentation presented at the American Society of Clinical Oncology's 41st Annual Meeting. Orlando, Florida, May 13-17, 2005.
18. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-1092.
19. Boccardo F, Ruhagotti A, Amoroso D, et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Abstract presented at the 26th Annual San Antonio Breast Cancer Symposium. San Antonio, Texas, December 3-6, 2005.
20. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-462.
21. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-1271.
22. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23:5138-5147.
23. Femara [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2004.
24. Carlson RW, Anderson BO, Bensinger W. Breast cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 2003;1:148-188.
25. Carlson RW, Anderson BO, Burstein HJ, et al. Breast cancer. J Natl Compr Canc Netw 2005;3:238-289.
26. NCCN Breast Cancer Clinical Practice Guidelines in Oncology, version 2, 2006. Available at: http://www.nccn.org/professionals/physician_gls/PDF/breast. pdf. Accessed October 5, 2006.
27. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol 2002;20:3317-3327.
28. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol 2003;21:2597-2599.
29. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619-629.
30. Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357-3365.
31. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-1583.
32. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-1802.